KEYTRUDA is approved for Patients with Recurrent or Metastatic Head and Neck Cancer

#Keytruda is approved at a fixed dose of 200 mg formulation of #Pembrolizumab administered every 3 weeks for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

To evaluate the safety Keytruda, researchers enrolled 192 patients with metastatic or recurrent HNSCC and ECOG performance status zero or 1. Efficacy was assessed in 174 out of the patients who had progression of disease or after the platinum-containing chemotherapy is administered on metastatic or recurrent HNSCC, or after the platinum-containing chemotherapy is administered as part of the induction, concurrent or adjuvant therapy.

Ninety- five percent of the patients enrolled underwent prior radiation therapy , with a median number of prior treatment lines for HNSCC is 2. Participants received 10 mg / Hg Keytruda every 2 weeks (n = 53 ) or 200 mg fixed dose every 3 weeks ( n = 121 ) until disease progression or unacceptable toxicity occurred disease.

Merck’s KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumor cells, by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck drug Keytruda is effective against below cancers :-

Melanoma – Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma at a dose of 2 mg/kg every three weeks.

Lung Cancer – Keytruda is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test with disease progression on or after platinum-containing chemotherapy, at a dose of 2 mg/kg every three weeks.

Head and Neck Cancer – Keytruda is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy at a fixed dose of 200 mg every three weeks.

Content Source: Drugs.com

Approximate Price for 4 vials of KEYTRUDA 50 mg is $8788.00